Open access
Aug 2026
Gp120-Activated Allogeneic Regulatory T cells for Prevention of Graft-versus-Host-Disease - a First-in-Human Trial.
These first clinical data support the feasibility and favorable safety profile of ATreg, a third-party, gp120-activated Treg product requiring no ex vivo expansion, and warrant further evaluation in larger prospective clinical trials.
A. Tuettenberg, L. Ruhnke, J. Schlöder et al.
· Transplantation and Cellular... · 0 citations